

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and NanoMedicine Innovation Center, LLC

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the UMOR Conflict of Interest Review Committee. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Committee and agreed to by the parties involved.

This proposed research agreement (“Agreement”) falls under the State of Michigan Conflict of Interest Statute because Professor Duxin Sun is an employee of the University of Michigan (“University”), and a partial owner of NanoMedicine Innovation Center, LLC. The law permits such an Agreement provided it is disclosed to the Board of Regents (“Regents”) of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Dr. Duxin Sun, a Professor in the Department of Pharmaceutical Sciences, is the partial owner of the for-profit company called NanoMedicine Innovation Center, LLC (the “Company”). The Company wishes to fund a project entitled “Formulation Based Paclitaxel Tumor and Tissue Localization by Mass Spectrometry Imaging in non-carrier strain (FVB) and PyMT transgenic mouse model of Breast Cancer” (ORSP #18-PAF07396) in the Department of Clinical Pharmacy under the direction of Dr. Manjunath Pai. The purpose of this project is quantification of biodistribution in mice with four paclitaxel formulations by the intravenous route of administration.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed \$551,201. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreement will support an effort by Dr. Pai to use his expertise and University laboratory, as well as other University resources, to characterize single-dose tumor localization of paclitaxel in multiple mouse models.

Recommendations:

This matter has been reviewed and approved by the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with NanoMedicine Innovation Center, LLC.

Respectfully submitted,

A handwritten signature in blue ink, appearing to read 'S. Jack Hu', is positioned above the printed name.

S. Jack Hu
Vice President for Research

June 2018